Enlivex Therapeutics
1D
1W
1M
3M
YTD
1Y
5Y
ALL
Why Robinhood?
Robinhood gives you the tools you need to put your money in motion. You can buy or sell ENLV and other ETFs, options, and stocks.About ENLV
Enlivex Therapeutics Ltd. engages in the development of macrophage reprogramming immunotherapy products. It focuses on the development of Allocetra, a universal off-the-shelf cell therapy designed to reprogram macrophages into their homeostatic state.
CEOOren Hershkovitz
CEOOren Hershkovitz
Employees36
Employees36
HeadquartersNess Ziona, Tel Aviv
HeadquartersNess Ziona, Tel Aviv
Founded2012
Founded2012
Employees36
Employees36
ENLV Key Statistics
Market cap18.55M
Market cap18.55M
Price-Earnings ratio-1.40
Price-Earnings ratio-1.40
Dividend yield—
Dividend yield—
Average volume710.74K
Average volume710.74K
High today$0.8221
High today$0.8221
Low today$0.73
Low today$0.73
Open price$0.79
Open price$0.79
Volume406.91K
Volume406.91K
52 Week high$2.10
52 Week high$2.10
52 Week low$0.73
52 Week low$0.73
Stock Snapshot
The current Enlivex Therapeutics(ENLV) stock price is $0.75, with a market capitalization of 18.55M. The stock trades at a price-to-earnings (P/E) ratio of -1.40.
On 2025-12-28, Enlivex Therapeutics(ENLV) stock traded between a low of $0.73 and a high of $0.82. Shares are currently priced at $0.75, which is +2.4% above the low and -9.0% below the high.
The Enlivex Therapeutics(ENLV)'s current trading volume is 406.91K, compared to an average daily volume of 710.74K.
In the last year, Enlivex Therapeutics(ENLV) shares hit a 52-week high of $2.10 and a 52-week low of $0.73.
In the last year, Enlivex Therapeutics(ENLV) shares hit a 52-week high of $2.10 and a 52-week low of $0.73.
People also own
Based on the portfolios of people who own ENLV. This list is generated using Robinhood data, and it’s not a recommendation.